# Mark F. Brady

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mark-f-brady/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,861 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 54 |
| i10-index | 92 |
| Last Known Institution | Roswell Park Comprehensive Cancer Center |
| OpenAlex ID | https://openalex.org/A5063378114 |
| ORCID iD | https://orcid.org/0000-0001-6700-2981 |
| Works | 166 |

## Researcher papers

- [Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-cancer/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Inherited Mutations in Women With Ovarian Carcinoma](https://scholariq.org/papers/inherited-mutations-in-women-with-ovarian-carcinoma/)
- [Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup](https://scholariq.org/papers/evaluation-of-new-platinum-based-treatment-regimens-in-advanced-stage-ovarian/)
- [Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)](https://scholariq.org/papers/bevacizumab-for-advanced-cervical-cancer-final-overall-survival-and-adverse/)
- [Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction/)
- [Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/final-overall-survival-of-a-randomized-trial-of-bevacizumab-for-primary/)
- [Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma](https://scholariq.org/papers/secondary-surgical-cytoreduction-for-advanced-ovarian-carcinoma/)
- [Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer](https://scholariq.org/papers/weekly-vs-every-3-week-paclitaxel-and-carboplatin-for-ovarian-cancer/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Reproductive Biology and Fertility](https://scholariq.org/topics/reproductive-biology-and-fertility/)

## Researcher university

- [Roswell Park Comprehensive Cancer Center](https://scholariq.org/institutions/roswell-park-comprehensive-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.